Mereo BioPharma logo

Mereo BioPharmaNASDAQ: MREO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

24 April 2019

Next earnings report:

27 March 2025

Last dividends:

N/A

Next dividends:

N/A
$549.22 M
-27%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector
-50%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 105 min ago
$3.54+$0.04(+1.14%)

Dividend

No data over the past 3 years
$6.59 M$11.37 M

Analysts recommendations

Institutional Ownership

MREO Latest News

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
globenewswire.com14 November 2024 Sentiment: POSITIVE

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT.

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com12 November 2024 Sentiment: POSITIVE

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the Company believes will provide runway into 2027, through multiple key inflection points.

Verde's assays of over 1,500m of drilling find rare earths up to 12,487 ppm TREO and 3,357 ppm MREO
globenewswire.com29 October 2024 Sentiment: POSITIVE

Results from 13 new holes show an 89m thick mineralized zone with grades up to 3,706 ppm TREO and 839 ppm MREO Results from 13 new holes show an 89m thick mineralized zone with grades up to 3,706 ppm TREO and 839 ppm MREO

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024, which includes the net proceeds of the Company's $50 million registered direct offering in June 2024.

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
globenewswire.com14 June 2024 Sentiment: POSITIVE

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.

MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research12 April 2024 Sentiment: NEUTRAL

The intense selling pressure on MEREO BIOPHARMA (MREO) may have subsided as it is currently in oversold territory. Along with this technical indicator, the consensus among analysts on Wall Street raising earnings estimates suggests that the stock is primed for a turnaround.

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
GlobeNewsWire21 September 2023 Sentiment: POSITIVE

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.

What type of business is Mereo BioPharma?

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

What sector is Mereo BioPharma in?

Mereo BioPharma is in the Healthcare sector

What industry is Mereo BioPharma in?

Mereo BioPharma is in the Biotechnology industry

What country is Mereo BioPharma from?

Mereo BioPharma is headquartered in United Kingdom

When did Mereo BioPharma go public?

Mereo BioPharma initial public offering (IPO) was on 24 April 2019

What is Mereo BioPharma website?

https://www.mereobiopharma.com

Is Mereo BioPharma in the S&P 500?

No, Mereo BioPharma is not included in the S&P 500 index

Is Mereo BioPharma in the NASDAQ 100?

No, Mereo BioPharma is not included in the NASDAQ 100 index

Is Mereo BioPharma in the Dow Jones?

No, Mereo BioPharma is not included in the Dow Jones index

When was Mereo BioPharma the previous earnings report?

No data

When does Mereo BioPharma earnings report?

The next expected earnings date for Mereo BioPharma is 27 March 2025